Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
Clinical trial NCT05577702 · COMPLETED
Trial details
- NCT number
- NCT05577702
- Sponsor
- BeiGene
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-08
- Primary completion
- 2024-12-13
- Enrollment
- 121
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.